Expression of Toll-like receptor 4 and beta 1 integrin in breast cancer

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 486-494

  Petricevic, B ^a,b   Vrbanec, D ^c   Jakic Razumovic, J ^c   Brcic, I ^c   Rabic, D ^d   Badovinac, T ^c   Ozimec, E ^e   Bali, V ^f  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c KBC Zagreb   (Croatia)

^d SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^e Zabok General Hospital   (Croatia)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Breast cancer; Integrin; Toll like receptor

Indexed keywords

BETA1 INTEGRIN; TOLL LIKE RECEPTOR 4; TLR4 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; BREAST TUMOR; CANCER STAGING; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; LUNG CARCINOMA; METABOLISM; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD29; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TOLL-LIKE RECEPTOR 4;

EID: 84866267024     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9885-0     Document Type: Article

References (53)

1. O'Neill LA. When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction. Immunity. 2008;29:12-20.
2. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene. 2008;27(2):218-24.
3. Ren T, et al. Functional expression of TLR9 is associated to the metastatic potential of human lung cancer cell. Cancer Biol Ther. 2007;6(11):1704-9.
4. He W, et al. TLR4 signalling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol. 2007;44(11):2850-9.
5. Zhang YB, et al. Increased expression of Toll-like receptors 4 and 9 in human lung cancer. Mol Biol Rep. 2009;36(6):1475-81.
6. Droemann D, et al. Human lung cancer cells express functionally active Toll-like receptor 9. Resp Res. 2005;6:1-10.
7. Kelly MG, et al. TLR-4 signalling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006;66(7):3859-68.
8. Merrell MA, et al. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res. 2006;4(7):437-47.
9. Ilvesaro JM, et al. Toll-like receptor 9 agonists stimulate prostate cancer invasion in vitro. Prostate. 2007;67:774-81.
10. Xie W, et al. Toll-like receptor 2 mediates invasion via activating NF-jB in MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun. 2009;379(4):1027-32.
11. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol. 2006;176(8):4894-901.
12. Zaks-Zilberman M, Zaks TZ, Vogel SN. Induction of proinflammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol) in murine and human breast cancer cell lines. Cytokine. 2001;15:156-65.
13. Stroinigg N, Srivastava MD. Modulation of toll-like receptor 7 and LL-37 expression in colon and breast epithelial cells by human beta-defensin-2. MD Allergy Asthma Proc. 2005;26(4): 299-309.
14. Yang H, et al. Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res. 2010;29:92-9.
15. Gonzalez-Reyes S, et al. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer. 2010;10(1):665-74.
16. Harmey JH, et al. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer. 2002;101:415-22.
17. Wang JH, et al. Endotoxin/lipopolysaccharide activates NFkappa B and enhances tumor cell adhesion and invasion through a beta 1 integrin-dependent mechanism. J Immunol. 2003;170: 795-804.
18. Hemler ME, Mannion BA, Berditchievski F. Association of TM4SF proteins with integrins: relevance to cancer. Biochem Biophys Acta. 1996;1287:67-71.
19. Varmer JA, Cheresh DA. Integrins and cancer. Curr Opin Cell Biol. 1996;8:724-30.
20. Arai K, Asakura T, Nemir P. Effect of local tumor removal and retained oncolysate on lung metastasis. J Surg Res. 1992;53:30-8.
21. Watson RW, Redmond HP, McCarthy J, Burke PE, Bouchier-Hayes D. Exposure of the peritoneal cavity to air regulates early inflammatory responses to surgery in a murine model. Br J Surg. 1995;82:1060-5.
22. Pidgeon GP, et al. The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease. Br J Cancer. 1999;81:1311-7.
23. Ridley AJ. Rho GTPases and cell migration. J Cell Sci. 2001; 114(15):2713-22.
24. Morini M, et al. The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int J Cancer. 2000;87(3):336-42.
25. Felding-Habermann B, et al. Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells. Clin Exp Metastasis. 2002;19(5):427-36.
26. Hofmann UB, et al. Coexpression of integrin alpha (v) beta3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression. J Invest Dermatol. 2000;115(4):625-32.
27. Hofmann UB, Westphal JR, Van Kraats AA, Ruiter DJ, Van Muijen GN. Expression of integrin alpha (v) beta (3) correlates with activation of membrane-type matrix metalloproteinase-1 (MT1-MMP) and matrix metalloproteinase-2 (MMP-2) in human melanoma cells in vitro and in vivo. Int J Cancer. 2000;87(1): 12-9.
28. Miyamoto S, Teramoto H, Gutkind JS, Yamada KM. Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors. J Cell Biol. 1996;135:1633-42.
29. Moro L, et al. Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion-dependent cell survival. EMBO J. 1998;17(22):6622-32.
30. Guo W, et al. Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell. 2006;126(3):489-502.
31. Gambaletta D, et al. Cooperative signaling between alpha (6) beta (4) integrin and ErbB-2 receptor is required to promote phosphatidylinositol 3-kinase-dependent invasion. Biol Chem. 2000; 275(14):10604-10.
32. Bill HM, et al. Epidermal growth factor receptor-dependent regulation of integrin-mediated signaling and cell cycle entry in epithelial cells. Mol Cell Biol. 2004;24(19):8586-99.
33. Yoon SO, Shin S, Lipscomb EA. A novel mechanism for integrin- mediated ras activation in breast carcinoma cells: the alpha 6 beta 4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling. Cancer Res. 2006;66(5):2732-9.
34. Oshita F, et al. High expression of integrin ß1 and p53 is a greater poor prognostic factor than clinical stage in small-cell lung cancer. Am J Clin Oncol. 2004;27:215-9.
35. Bottger TC, et al. Prognostic value of immunohistochemical expression of ß-1 integrin in pancreatic carcinoma. Oncology. 1999;56:308-13.
36. Nikkola J, et al. Integrin chains ß1 and av as prognostic factors in human metastatic melanoma. Melanoma Res. 2004;14:29-37.
37. Gui GP, et al. Integrin expression in primary breast cancer and its relation to axillary nodal status. Surgery. 1995;117:102-8.
38. Jonjic N, Lucin K, Krstulja M, Iternicka Z, Mustac E. Expression of ß-1 integrins on tumor cells of invasive ductal breast carcinoma. Pathol Res Pract. 1993;189:979-84.
39. Tavassoli FA, Devilee P. World health organisation classification of tumors. Lyon: IARC Press; 2003. p. 26.
40. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-10.
41. Taylor CR. The current role of immunohistochemistry in diagnostic pathology. Adv Pathol Lab Med. 1994;7:59-65.
42. Bartlett JMS, et al. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol. 2001;195:422-8.
43. Wang EL, et al. High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer. 2010;102(5):908-15.
44. White DE, Muller WJ. Multifaceted roles of integrins in breast cancer metastasis. J Mammary Gland Biol Neoplasia. 2007;12: 135-42.
45. Gonzalez MA, et al. An immunohistochemical examination of the expression of E-cadherin, alpha- and beta/gamma-catenins, and alpha2- and beta1-integrins in invasive breast cancer. J Pathol. 1999;187(5):523-9.
46. Berry MG, Gui GP, Wells CA, Carpenter R. Integrin expression and survival in human breast cancer. Eur J Surg Oncol. 2004; 30(5):484-9.
47. Diaz LK, et al. Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer. Mod Pathol. 2005;18(9):1165-75.
48. Lesniak D, et al. Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor- 2-positive breast cancer. Cancer Res. 2009;69(22):8620-8.
49. Friedrichs K, et al. High expression level of alpha 6 integrin in human breast carcinoma is correlated with reduced survival. Cancer Res. 1995;55(4):901-6.
50. Bergamaschi A, et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol. 2008;214(3):357-67.
51. Gasparini G, et al. Vascular integrin alpha (v)beta 3: a new prognostic indicator in breast cancer. Clin Cancer Res. 1998; 4(11):2625-34.
52. Serre CM, Clezardin P, Frappart L, Boivin G, Delmas PD. Distribution of thrombospondin and integrin alpha V in DCIS, invasive ductal and lobular human breast carcinomas. Analysis by electron microscopy. Virchows Arch. 1995;427(4):365-72.
53. Lanzafame S, Emmanuele C, Torrisi A. Correlation of alpha 2 beta 1 integrin expression with histological type and hormonal receptor status in breast carcinomas. Pathol Res Pract. 1996; 192(10):1031-8.